CDK control pathways integrate cell size and ploidy information to control cell division

  1. James Oliver Patterson  Is a corresponding author
  2. Souradeep Basu  Is a corresponding author
  3. Paul Rees
  4. Paul Nurse
  1. The Francis Crick Institute, United Kingdom
  2. Swansea University, United Kingdom

Abstract

Maintenance of cell size homeostasis is a property that is conserved throughout eukaryotes. Cell size homeostasis is brought about by the co-ordination of cell division with cell growth, and requires restriction of smaller cells from undergoing mitosis and cell division, whilst allowing larger cells to do so. Cyclin-CDK is the fundamental driver of mitosis and therefore ultimately ensures size homeostasis. Here we dissect determinants of CDK activity in vivo to investigate how cell size information is processed by the cell cycle network in fission yeast. We develop a high-throughput single-cell assay system of CDK activity in vivo and show that inhibitory tyrosine phosphorylation of CDK encodes cell size information, with the phosphatase PP2A aiding to set a size threshold for division. CDK inhibitory phosphorylation works synergistically with PP2A to prevent mitosis in smaller cells. Finally, we find that diploid cells of equivalent size to haploid cells exhibit lower CDK activity in response to equal cyclin-CDK enzyme concentrations, suggesting that CDK activity is reduced by increased DNA levels. Therefore, scaling of cyclin-CDK levels with cell size, CDK inhibitory phosphorylation, PP2A, and DNA-dependent inhibition of CDK activity, all inform the cell cycle network of cell size, thus contributing to cell-size homeostasis.

Data availability

Analysed data has been uploaded to Figshare with the handle 10779/crick.14633037.

The following data sets were generated

Article and author information

Author details

  1. James Oliver Patterson

    Cell Cycle Laboratory, The Francis Crick Institute, London, United Kingdom
    For correspondence
    jamesop@gmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1993-4500
  2. Souradeep Basu

    Cell Cycle Laboratory, The Francis Crick Institute, London, United Kingdom
    For correspondence
    saz.basu@crick.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4448-8688
  3. Paul Rees

    College of Engineering, Swansea University, Swansea, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Paul Nurse

    Cell Cycle Laboratory, The Francis Crick Institute, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Funding

Boehringer Ingelheim Fonds

  • James Oliver Patterson

Cancer Research UK (FC01121)

  • James Oliver Patterson
  • Souradeep Basu
  • Paul Nurse

Medical Research Council (FC01121)

  • James Oliver Patterson
  • Souradeep Basu
  • Paul Nurse

Wellcome Trust (FC01121)

  • James Oliver Patterson
  • Paul Rees
  • Paul Nurse

Wellcome Trust (214183)

  • James Oliver Patterson
  • Souradeep Basu
  • Paul Nurse

The Lord Leonard and Lady Estelle Wolfson Foundation

  • James Oliver Patterson
  • Souradeep Basu
  • Paul Nurse

Biotechnology and Biological Sciences Research Council (BB/P026818/1)

  • James Oliver Patterson
  • Paul Rees

Biotechnology and Biological Sciences Research Council (BB/N005163/1)

  • Paul Rees

National Science Foundation (1458626)

  • Paul Rees

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Patterson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,252
    views
  • 529
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James Oliver Patterson
  2. Souradeep Basu
  3. Paul Rees
  4. Paul Nurse
(2021)
CDK control pathways integrate cell size and ploidy information to control cell division
eLife 10:e64592.
https://doi.org/10.7554/eLife.64592

Share this article

https://doi.org/10.7554/eLife.64592

Further reading

    1. Cell Biology
    Jittoku Ihara, Yibin Huang ... Koichi Yamamoto
    Research Article

    Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.

    1. Cell Biology
    Qi Zeng, Chen Yao ... Shuai Chen
    Research Article

    Mounting evidence has demonstrated the genetic association of ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) gene polymorphisms with bronchial asthma and a diverse set of inflammatory disorders. However, its role in type I interferon (type I IFN) signaling remains poorly defined. Herein, we report that ORMDL3 is a negative modulator of the type I IFN signaling by interacting with mitochondrial antiviral signaling protein (MAVS) and subsequently promoting the proteasome-mediated degradation of retinoic acid-inducible gene I (RIG-I). Immunoprecipitation coupled with mass spectrometry (IP-MS) assays uncovered that ORMDL3 binds to ubiquitin-specific protease 10 (USP10), which forms a complex with and stabilizes RIG-I through decreasing its K48-linked ubiquitination. ORMDL3 thus disrupts the interaction between USP10 and RIG-I, thereby promoting RIG-I degradation. Additionally, subcutaneous syngeneic tumor models in C57BL/6 mice revealed that inhibition of ORMDL3 enhances anti-tumor efficacy by augmenting the proportion of cytotoxic CD8 positive T cells and IFN production in the tumor microenvironment (TME). Collectively, our findings reveal the pivotal roles of ORMDL3 in maintaining antiviral innate immune responses and anti-tumor immunity.